Maravai Lifesciences Holdings, Inc. SEC Filings

Maravai Lifesciences Holdings, Inc. (MRVI) reported an insider purchase by its Chief Executive Officer and director, Bernd Brust. On 11/13/2025, Brust, through The Bernd Brust Management Trust, purchased 216,212 shares of Class A common stock in an open-market transaction coded "P". The weighted average purchase price was $3.25 per share, with individual trade prices ranging from $3.235 to $3.25. Following this transaction, the trust beneficially owned 466,771 shares of Class A common stock held indirectly, and an additional 2,000,000 shares were listed as held directly.

Maravai LifeSciences Holdings (MRVI) reported insider purchases on Form 4 by CEO and Director Bernd Brust. The filing shows two open‑market buys of Class A common stock: 157,201 shares on 11/11/2025 at a weighted average price of $3.24 and 93,358 shares on 11/12/2025 at a weighted average price of $3.21, executed through The Bernd Brust Management Trust.

Following these transactions, the table lists 250,559 shares indirectly owned via the trust and 2,000,000 shares directly owned. Prices reflect weighted averages across multiple trades within the disclosed ranges.

Maravai LifeSciences (MRVI) reported a weaker Q3 2025 as revenue fell to $41.6 million from $69.0 million a year ago, driven by lower Nucleic Acid Production demand. The quarter posted a net loss attributable to MRVI of $25.6 million (basic and diluted loss per share $0.18) with a loss from operations of $41.0 million.

Year to date, revenue was $135.9 million versus $202.6 million in 2024, and the operating loss reached $156.5 million. Results include a $42.9 million goodwill impairment taken earlier in 2025 and a Q3 $7.4 million restructuring charge tied to a plan that reduces the workforce by about 25% and narrows facilities.

By segment in Q3, Nucleic Acid Production delivered $25.4 million and Biologics Safety Testing $16.3 million. Cash and cash equivalents were $243.6 million at September 30, down from $322.4 million at year end, as operating activities used $34.8 million year‑to‑date. The company closed two tuck‑in deals in 2025: Molecular Assemblies assets for $11.2 million and Officinae Bio for $15.1 million, adding developed technologies to support RNA/DNA workflows.

Maravai LifeSciences Holdings, Inc. furnished an Item 2.02 report stating it issued a press release announcing financial results for the third quarter of 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated by reference unless expressly specified.

Maravai LifeSciences (MRVI) announced that three directors—Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD—voluntarily resigned effective October 21, 2025 as part of efforts to rationalize its Board size and reduce administrative costs. The Board will shrink from 11 to 8 directors effective October 27, 2025, and the company noted the departures were not due to any disagreement with management or the Board.

Following the changes, R. Andrew Eckert was appointed chair of the Nominating, Governance and Risk Committee and joined the Audit Committee, while Gregory T. Lucier joined the Nominating, Governance and Risk Committee. The Board also accelerated the vesting of all unvested restricted stock unit awards held by the departing directors as of the effective date.

Maravai LifeSciences reported a weaker first half of 2025 with total revenue of $94.2 million versus $133.6 million in the prior-year six-month period, and second-quarter revenue of $47.4 million versus $69.4 million a year earlier. The company recorded a consolidated net loss of $122.7 million for the six months, of which $69.5 million was attributable to Maravai and $53.2 million to non-controlling interests. Operating results were materially affected by $42.9 million of goodwill impairment recognized in the six months.

Balance sheet highlights show $269.9 million of cash and cash equivalents and $896.97 million of total assets at June 30, 2025, down from $322.4 million cash and $1.008 billion total assets at year-end. The company completed two small acquisitions—Molecular Assemblies (asset purchase, ~$11.2M) and Officinae Bio (~$15.1M)—and recorded related intangible assets and goodwill. A government cooperative agreement provided a $38.8 million award for facility construction, and contingent consideration of $4.94 million was recorded as of June 30, 2025.

Maravai LifeSciences announced a corporate restructuring to reduce operating costs, including a workforce reduction that management committed to on August 8, 2025. The company expects the reduction to affect approximately 25% of its workforce and estimates restructuring and related costs of $8.0 million to $9.0 million, primarily for severance and benefits, with the majority expected to be recognized in the second half of 2025. The company cautions the estimate is based on current assumptions and actual amounts may differ or include additional costs.

The Board eliminated two executive roles on August 7, 2025, resulting in the planned departures of Rebecca Buzzeo, Executive VP and Chief Commercial Officer, and Pete Leddy, Ph.D., Executive VP and Chief Administrative Officer, with expected last days of employment in September and October 2025. Their termination is treated as without "cause" under their agreements, and severance amounts are included in the estimated restructuring costs, subject to execution of separation agreements and releases. The press release with second-quarter results is furnished as Exhibit 99.1.

Maravai LifeSciences Holdings, Inc. (MRVI) – Form 4 insider filing dated 07/11/2025

Director Gregory T. Lucier reported an internal reclassification of ownership that occurred on 07/10/2025. The transaction was coded “G,” indicating a gift rather than an open-market sale or purchase.

• Securities involved: 89,139 Class A common shares.
• From → To: Shares transferred from direct ownership to an indirect family partnership.
• Post-transfer holdings: 55,123 shares remain in Lucier’s direct account; 109,784 shares are now held indirectly via the family partnership.
• Consideration: $0; no cash changed hands.

The footnote clarifies that Lucier disclaims beneficial ownership except for his pecuniary interest. The spouse is general partner of the family partnership, which now exercises voting and dispositive power over the transferred shares.

No derivative securities were reported. Because the event is a non-monetary, insider-to-family transfer, it does not alter the company’s share count, earnings outlook, or insider net exposure. It mainly reflects personal estate or tax planning and carries minimal direct market impact.